$INBP
INTEGRATED BIOPHARMA INC

2024 Q4 Form 10-Q Financial Statement

#000143774924034953 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $13.62M $12.92M
YoY Change 5.44% 4.78%
Cost Of Revenue $12.25M $12.08M
YoY Change 1.35% 6.66%
Gross Profit $1.371M $832.0K
YoY Change 64.78% -16.55%
Gross Profit Margin 10.07% 6.44%
Selling, General & Admin $881.0K $886.0K
YoY Change -0.56% -8.38%
% of Gross Profit 64.26% 106.49%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $88.00K $77.00K
YoY Change 14.29% -12.5%
% of Gross Profit 6.42% 9.25%
Operating Expenses $881.0K $886.0K
YoY Change -0.56% -8.38%
Operating Profit $490.0K -$54.00K
YoY Change -1007.41% -280.0%
Interest Expense $14.00K -$8.000K
YoY Change -275.0% -161.54%
% of Operating Profit 2.86%
Other Income/Expense, Net $8.000K
YoY Change -157.14%
Pretax Income $504.0K -$46.00K
YoY Change -1195.65% -387.5%
Income Tax $245.0K $13.00K
% Of Pretax Income 48.61%
Net Earnings $259.0K -$59.00K
YoY Change -538.98% 68.57%
Net Earnings / Revenue 1.9% -0.46%
Basic Earnings Per Share $0.01 $0.00
Diluted Earnings Per Share $0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 30.10M 30.10M 29.95M
Diluted Shares Outstanding 30.65M 29.97M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.271M $2.590M
YoY Change -12.32% 121.75%
Cash & Equivalents $2.271M $2.594M
Short-Term Investments
Other Short-Term Assets $432.0K $482.0K
YoY Change -10.37% -6.59%
Inventory $11.22M $10.51M
Prepaid Expenses
Receivables $4.385M $4.172M
Other Receivables $0.00 $0.00
Total Short-Term Assets $18.31M $17.76M
YoY Change 3.11% 4.08%
LONG-TERM ASSETS
Property, Plant & Equipment $1.853M $1.636M
YoY Change 13.26% -11.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.460M $4.780M
YoY Change -6.69% -0.52%
Total Long-Term Assets $7.871M $8.883M
YoY Change -11.39% -4.49%
TOTAL ASSETS
Total Short-Term Assets $18.31M $17.76M
Total Long-Term Assets $7.871M $8.883M
Total Assets $26.18M $26.64M
YoY Change -1.72% 1.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.763M $3.536M
YoY Change -21.86% 0.2%
Accrued Expenses $3.266M $2.620M
YoY Change 24.66% 16.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $40.00K
YoY Change -100.0% -4.76%
Total Short-Term Liabilities $6.029M $6.197M
YoY Change -2.71% 6.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $604.0K $1.560M
YoY Change -61.28% -17.46%
Total Long-Term Liabilities $604.0K $1.560M
YoY Change -61.28% 3900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.029M $6.197M
Total Long-Term Liabilities $604.0K $1.560M
Total Liabilities $6.633M $7.756M
YoY Change -14.48% 0.17%
SHAREHOLDERS EQUITY
Retained Earnings -$31.97M -$32.40M
YoY Change -1.33% 0.18%
Common Stock $60.00K $60.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.55M $18.89M
YoY Change
Total Liabilities & Shareholders Equity $26.18M $26.64M
YoY Change -1.72% 1.05%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income $259.0K -$59.00K
YoY Change -538.98% 68.57%
Depreciation, Depletion And Amortization $88.00K $77.00K
YoY Change 14.29% -12.5%
Cash From Operating Activities $657.0K $1.313M
YoY Change -49.96% 32.36%
INVESTING ACTIVITIES
Capital Expenditures $56.00K $38.00K
YoY Change 47.37% -24.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$56.00K -$38.00K
YoY Change 47.37% -24.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$7.000K $3.000K
YoY Change -333.33% -102.86%
NET CHANGE
Cash From Operating Activities $657.0K $1.313M
Cash From Investing Activities -$56.00K -$38.00K
Cash From Financing Activities -$7.000K $3.000K
Net Change In Cash $594.0K $1.278M
YoY Change -53.52% 52.69%
FREE CASH FLOW
Cash From Operating Activities $657.0K $1.313M
Capital Expenditures $56.00K $38.00K
Free Cash Flow $601.0K $1.275M
YoY Change -52.86% 35.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 dei Entity Registrant Name
EntityRegistrantName
INTEGRATED BIOPHARMA INC
CY2024Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001016504
CY2024Q3 dei Amendment Flag
AmendmentFlag
false
CY2024Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30134510
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30099610
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
34900
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
34900
CY2024Q3 inbp Repayments Of Long Term Capital Lease Obligations Including Interest
RepaymentsOfLongTermCapitalLeaseObligationsIncludingInterest
217000 usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2024Q3 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 pure
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 dei Document Type
DocumentType
10-Q
CY2024Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 dei Entity File Number
EntityFileNumber
001-31668
CY2024Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-2407475
CY2024Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
225 Long Ave.
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Hillside
CY2024Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07205
CY2024Q3 dei City Area Code
CityAreaCode
888
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
319-6962
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30099610
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13617000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12915000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12246000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12083000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
1371000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
832000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
881000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
886000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
490000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-54000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
-14000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
-8000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
504000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
245000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
259000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-59000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30099610
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29965914
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
550367
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30649977
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29965914
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2271000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1677000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4385000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4668000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
11224000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
11244000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
432000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
286000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
18312000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
17895000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1853000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1885000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1558000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1790000 usd
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4404000 usd
CY2024Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4601000 usd
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
56000 usd
CY2024Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
56000 usd
CY2024Q3 us-gaap Assets
Assets
26183000 usd
CY2024Q2 us-gaap Assets
Assets
26207000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2763000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2510000 usd
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2312000 usd
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2661000 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0 usd
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
7000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
954000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
945000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6029000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6123000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
604000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
846000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
6633000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
6969000 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
60000 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
60000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
51557000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
51504000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31968000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32227000 usd
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
99000 usd
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
99000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
19550000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
19238000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26183000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26207000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
19238000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
53000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
259000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
19550000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
18861000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
71000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-59000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
18886000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
259000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-59000 usd
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
88000 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
232000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
221000 usd
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
53000 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
71000 usd
CY2024Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
197000 usd
CY2023Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
8000 usd
CY2024Q3 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
3000 usd
CY2023Q3 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
3000 usd
CY2024Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-283000 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-339000 usd
CY2024Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-20000 usd
CY2023Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
250000 usd
CY2024Q3 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
149000 usd
CY2023Q3 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
201000 usd
CY2024Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
253000 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1251000 usd
CY2024Q3 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-350000 usd
CY2023Q3 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
74000 usd
CY2024Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-232000 usd
CY2023Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-221000 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
657000 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1313000 usd
CY2024Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56000 usd
CY2023Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38000 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56000 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38000 usd
CY2024Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2023Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000 usd
CY2024Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
7000 usd
CY2023Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
10000 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7000 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
594000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1278000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1677000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1316000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2271000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2594000 usd
CY2024Q3 us-gaap Interest Paid Net
InterestPaidNet
12000 usd
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
10000 usd
CY2024Q3 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
CY2023Q3 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
22000 usd
CY2024Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
69000 usd
CY2024Q3 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
190000 usd
CY2023Q3 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
6000 usd
CY2024Q3 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
54000 usd
CY2023Q3 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
7000 usd
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3694850
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4423183
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
8704000 usd
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7888000 usd
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1531000 usd
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2449000 usd
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
989000 usd
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
907000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
11224000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
11244000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9871000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9815000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8018000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7930000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1853000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1885000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
88000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
77000 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
253000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
250000 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3000 usd
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3000 usd
CY2024Q3 inbp Finance Lease Expense
FinanceLeaseExpense
3000 usd
CY2023Q3 inbp Finance Lease Expense
FinanceLeaseExpense
3000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1558000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
954000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
604000 usd
CY2024Q3 inbp Lease Commitment Amount
LeaseCommitmentAmount
1653000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1790000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
945000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
846000 usd
CY2024Q2 inbp Lease Commitment Amount
LeaseCommitmentAmount
1905000 usd
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
236000 usd
CY2024Q3 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
0 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
265000 usd
CY2023Q3 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
0 usd
CY2023Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
10000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
759000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
660000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
169000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
64000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1652000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
95000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1557000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0396 pure
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.317 pure
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4749183
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.34
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
200000
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.19
CY2024Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
667
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.41
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
33333
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.52
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4915183
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.33
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3821483
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.33
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13617000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
1371000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
88000 usd
CY2024Q3 us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
24000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12915000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
832000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
77000 usd
CY2023Q3 us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
38000 usd
CY2024Q3 us-gaap Assets
Assets
26183000 usd
CY2023Q2 us-gaap Assets
Assets
26207000 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001437749-24-034953-index-headers.html Edgar Link pending
0001437749-24-034953-index.html Edgar Link pending
0001437749-24-034953.txt Edgar Link pending
0001437749-24-034953-xbrl.zip Edgar Link pending
ex_737799.htm Edgar Link pending
ex_737800.htm Edgar Link pending
ex_737801.htm Edgar Link pending
ex_737802.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
inbp-20240930.xsd Edgar Link pending
inbp20240930_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
inbp-20240930_cal.xml Edgar Link unprocessable
inbp-20240930_def.xml Edgar Link unprocessable
inbp-20240930_lab.xml Edgar Link unprocessable
inbp-20240930_pre.xml Edgar Link unprocessable
inbp20240930_10q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending